{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:43:24Z","timestamp":1792035804307,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.drudis.2022.02.013","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T21:09:04Z","timestamp":1645218544000},"page":"1945-1953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Nucleosides and emerging viruses: A new story"],"prefix":"10.1016","volume":"27","author":[{"given":"Vincent","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi A.","family":"Agrofoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.02.013_b0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.apsb.2012.10.001","article-title":"Milestones in the discovery of antiviral agents: nucleosides and nucleotides","volume":"2","author":"De Clercq","year":"2012","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2022.02.013_b0010","series-title":"Acyclic, Carbocyclic and L-Nucleosides","author":"Agrofoglio","year":"1998"},{"key":"10.1016\/j.drudis.2022.02.013_b0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-3002(59)90597-9","article-title":"Synthesis and biological activities of iododeoxyuridine, an analog of thymidine","volume":"32","author":"Prusoff","year":"1959","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2022.02.013_b0020","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2022.02.013_b0025","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/cr00016a004","article-title":"AIDS-driven nucleoside chemistry","volume":"92","author":"Huryn","year":"1992","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2022.02.013_b0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates Cidofovir, Adefovir and Tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","author":"De Clercq","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2022.02.013_b0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.02.013_b0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2010.02.001","article-title":"Human and viral nucleoside\/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties","volume":"86","author":"Deville-Bonne","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.drudis.2022.02.013_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs \u2013 the development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"De Clercq","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2022.02.013_b0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.18388\/abp.1996_4553","article-title":"New insights regarding the potential of the pronucleotide approach in antiviral chemotherapy","volume":"43","author":"Gosselin","year":"1996","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.drudis.2022.02.013_b0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.antiviral.2011.08.015","article-title":"Application of kinase bypass trategies to nucleoside antivirals","volume":"92","author":"Ray","year":"2011","journal-title":"Antivir Res"},{"key":"10.1016\/j.drudis.2022.02.013_b0060","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/cr5002035","article-title":"Synthesis of nucleoside phosphate and phosphonate prodrugs","volume":"114","author":"Pradere","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2022.02.013_b0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-5793(94)00776-4","article-title":"Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase","volume":"351","author":"McGuigan","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.drudis.2022.02.013_b0070","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cmdc.200900289","article-title":"Aryloxy phosphoramidate triesters: a technology for delivering monophosphoralytaed nucleosides and sugars into cells","volume":"4","author":"Mehellou","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2022.02.013_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040206618775243","article-title":"Phosphoramidates and phosphonamidates (ProTides) with antiviral activity","volume":"26","author":"Slusarczyk","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.drudis.2022.02.013_b0080","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide prodrug technology: from the concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.013_b0085","doi-asserted-by":"crossref","first-page":"9411","DOI":"10.3390\/ijerph17249411","article-title":"Viral pandemics of the last four decades: pathophysiology, health impacts and perspectives","volume":"17","author":"Roychoudhury","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.drudis.2022.02.013_b0090","series-title":"Report of the WHO\/FAO\/OIE Joint Consultation on Emerging Zoonotic Diseases","author":"WHO","year":"2004"},{"key":"10.1016\/j.drudis.2022.02.013_b0095","doi-asserted-by":"crossref","first-page":"12411","DOI":"10.1073\/pnas.210382297","article-title":"Emerging viral diseases","volume":"97","author":"Nichol","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2022.02.013_b0100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s12276-021-00608-9","article-title":"Emerging and re-emerging fatal viral diseases","volume":"53","author":"Choi","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.drudis.2022.02.013_b0105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2019.00549","article-title":"Infectious disease threats in the twenty-first century: strengthening the global responses","volume":"10","author":"Bloom","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2022.02.013_b0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41564-018-0296-2","article-title":"Tracking virus outbreak in twenty-first century","volume":"4","author":"Grubaugh","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.drudis.2022.02.013_b0115","first-page":"167","article-title":"Emerging and re-emerging viruses in the era of globalization","volume":"7","author":"Zappa","year":"2009","journal-title":"Blood Transfus"},{"key":"10.1016\/j.drudis.2022.02.013_b0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/microbiolspec.OH-0001-2012","article-title":"RNA viruses: a case study of the biology of emerging infectious diseases","volume":"1","author":"Woolhouse","year":"2013","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.drudis.2022.02.013_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int J Antimicrob"},{"key":"10.1016\/j.drudis.2022.02.013_b0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virol.2018.12.009","article-title":"Diverse RNA viruses of arthropod origin in the blood of fruit bats suggest a link between bat and arthropod viromes","volume":"528","author":"Bennett","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2022.02.013_b0135","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00018-014-1785-y","article-title":"Detecting the emergence of novel, zoonotic viruses pathogenic to humans","volume":"72","author":"Rosenberg","year":"2015","journal-title":"Cell Mol Life"},{"key":"10.1016\/j.drudis.2022.02.013_b0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ilar\/ilx026","article-title":"Are RNA viruses candidate agents for the next global pandemic? A review","volume":"58","author":"Carrasco-Hernandez","year":"2017","journal-title":"ILAR J"},{"key":"10.1016\/j.drudis.2022.02.013_b0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrg2323","article-title":"Rates of evolutionary changes in viruses: patterns and determinants","volume":"9","author":"Duffy","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.drudis.2022.02.013_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040206618758524","article-title":"Addressing the selectivity and toxicity of antiviral nucleosides","volume":"26","author":"Feng","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.drudis.2022.02.013_b0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1359-6446(97)01047-7","article-title":"Structural requirements for antiviral activity in nucleosides","volume":"2","author":"Herdewijn","year":"1997","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2022.02.013_b0160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","article-title":"The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part I: Early structural modifications to the nucleoside","volume":"154","author":"Seley-Radtke","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.drudis.2022.02.013_b0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2018.11.016","article-title":"The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold","volume":"162","author":"Yates","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.drudis.2022.02.013_b0170","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1039\/D0CS01430C","article-title":"Recent progress in non-native nucleic acid modifications","volume":"50","author":"McKenzie","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2022.02.013_b0175","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1021\/acschembio.6b00714","article-title":"5-Substituted pyrimidine and 7-substituted 7-deazapurine dNTPs as substrates for DNA polymerases in competitive primer extension in presence of natural dNTPs","volume":"11","author":"Cahova","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2022.02.013_b0180","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/acsmedchemlett.1c00070","article-title":"Intriguing antiviral modified nucleosides: a retrospective view into the future treatment of COVID-19","volume":"12","author":"Ami","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.02.013_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2022.02.013_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139001","article-title":"Structural analysis of monomeric RNA-dependent polymerases: Evolutionary and therapeutic implications","volume":"10","author":"Jacome","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.02.013_b0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-981-10-8456-0_3","article-title":"Viral RNA-dependent RNA-polymerases: a structural over-view","volume":"88","author":"Ferrero","year":"2018","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.drudis.2022.02.013_b0200","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","volume":"71","author":"Te Velthuis","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2022.02.013_b0205","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/QCO.0000000000000212","article-title":"The future of antivirals: broad-spectrum inhibitors","volume":"28","author":"Debing","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.013_b0210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-021-01282-0","article-title":"Developing therapeutic approaches for twenty-first century emerging infectious viral diseases","volume":"27","author":"Meganck","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2022.02.013_b0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-2836(02)01033-1","article-title":"The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage","volume":"324","author":"Gorbalenya","year":"2002","journal-title":"J Mol Biol"},{"key":"10.1016\/j.drudis.2022.02.013_b0220","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/v10020076","article-title":"RNA dependent RNA polymerases: insights from structure, function and evolution","volume":"10","author":"Venkataraman","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2022.02.013_b0225","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/JVI.00080-16","article-title":"Homology-based indentification of a mutation in the coronavirus RNA-dependent RNA polymerases that confers resistance to multiple mutagens","volume":"90","author":"Sexton","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.02.013_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001005","article-title":"Quasispecies theory and the behavior of RNA viruses","volume":"6","author":"Lauring","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2022.02.013_b0235","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coviro.2014.09.017","article-title":"RNA replication errors and the evolution of virus pathogenicity and virulence","volume":"9","author":"Novella","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.drudis.2022.02.013_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000003","article-title":"Why are RNA virus mutation rates so damn high?","volume":"16","author":"Duffy","year":"2018","journal-title":"PLoS Biol"},{"key":"10.1016\/j.drudis.2022.02.013_b0245","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","article-title":"Ribavirin\u2019s antiviral mechanism of action: lethal mutagenesis ?","volume":"80","author":"Crotty","year":"2002","journal-title":"J Mol Med"},{"key":"10.1016\/j.drudis.2022.02.013_b0250","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00003495-200969020-00002","article-title":"Antimicrobial strategies: inhibition of viral polymerases by 3\u2019-hydroxyl nucleosides","volume":"69","author":"Deval","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2022.02.013_b0255","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.3390\/molecules25235695","article-title":"Targeting the RdRp of emerging RNA viruses: the structure\u2013based drug design challenge","volume":"25","author":"Picarazzi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.02.013_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040206620976786","article-title":"Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections","volume":"28","author":"Huchting","year":"2020","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.drudis.2022.02.013_b0265","doi-asserted-by":"crossref","first-page":"e02329","DOI":"10.1128\/mBio.02329-18","article-title":"Origins and evolution of the global RNA virome","volume":"9","author":"Wolf","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.drudis.2022.02.013_b0270","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","article-title":"Design, synthesis, and broad spectrum antiviral activity of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides","volume":"15","author":"Witkowski","year":"1972","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.013_b0275","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.02.013_b0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.drudis.2022.02.013_b0285","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eimc.2018.05.008","article-title":"Use of ribavirin in viruses other than hepatitis C. A review of the evidence","volume":"37","author":"Ramirez-Olivencia","year":"2019","journal-title":"Enferm Infect Microbiol Clin"},{"key":"10.1016\/j.drudis.2022.02.013_b0290","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.12998\/wjcc.v9.i19.5135","article-title":"Controversies\u2019 clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages","volume":"9","author":"Liatsos","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.drudis.2022.02.013_b0295","doi-asserted-by":"crossref","DOI":"10.1007\/7355_2018_37","article-title":"The discovery of sofosbuvir: a liver-targeted nucleotide prodrug for the treatment and cure of HCV","volume":"31","author":"Sofia","year":"2019","journal-title":"Topics Med. Chem."},{"key":"10.1016\/j.drudis.2022.02.013_b0300","series-title":"Hepatitis C Viruses: Genomes and Molecular Biology","article-title":"Chapter title","author":"Chevaliez","year":"2006"},{"key":"10.1016\/j.drudis.2022.02.013_b0305","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-d-2\u2019-deoxy-2\u2019-alpha-fluoro-2\u2019-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.013_b0310","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/AAC.00399-10","article-title":"PSI-7851, a pronucleotide of beta-D-2\u2019-deoxy-2\u2019-fluoro-2\u2019-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication","volume":"54","author":"Lam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.013_b0315","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1021\/jm201384j","article-title":"Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis virus NS5B RNA-dependent RNA polymerase","volume":"55","author":"Sofia","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.013_b0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227104","article-title":"Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus","volume":"15","author":"Good","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2022.02.013_b0325","doi-asserted-by":"crossref","first-page":"e02479","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1016\/j.drudis.2022.02.013_b0330","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/jm00007a014","article-title":"Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors","volume":"38","author":"Siddiqi","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.013_b0335","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/15257770701542165","article-title":"Synthesis of 1\u2019-C-fluoromethyladenosine","volume":"26","author":"Damont","year":"2007","journal-title":"Nucleos Nucleot Nucleic Acids"},{"key":"10.1016\/j.drudis.2022.02.013_b0340","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3762\/bjoc.14.65","article-title":"Recent advances in synthetic approaches to C-nucleosides","volume":"14","author":"Temburnikar","year":"2018","journal-title":"Beilstein J Org Chem"},{"key":"10.1016\/j.drudis.2022.02.013_b0345","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.013_b0350","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.02.013_b0355","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1039\/D0CP05948J","article-title":"1\u2019-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication","volume":"23","author":"Zhang","year":"2021","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.drudis.2022.02.013_b0360","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2017.06.011","article-title":"4\u2019-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency","volume":"144","author":"Hotard","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.drudis.2022.02.013_b0365","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2016.07.018","article-title":"Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus","volume":"133","author":"Eyer","year":"2016","journal-title":"Antivir Res"},{"key":"10.1016\/j.drudis.2022.02.013_b0370","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4149\/av_2017_01_48","article-title":"T-705 (Favipiravir) suppresses tumor necrosis factor \u03b1 production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug","volume":"61","author":"Tanaka","year":"2017","journal-title":"Acta Virol"},{"key":"10.1016\/j.drudis.2022.02.013_b0375","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.drudis.2022.02.013_b0380","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.02.013_b0385","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.drudis.2022.02.013_b0390","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.013_b0395","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cid\/ciaa1176","article-title":"AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II\/III multicenter randomized clinical trial","volume":"73","author":"Ivashchenko","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.013_b0400","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41594-021-00657-8","article-title":"Molnupiravir: coding for catastrophe","volume":"28","author":"Malone","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2022.02.013_b0405","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of monulpiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2022.02.013_b0410","doi-asserted-by":"crossref","first-page":"e01348","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral \u03b2-D-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.02.013_b0415","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2022.02.013_b0420","doi-asserted-by":"crossref","first-page":"e00766","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.013_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.drudis.2022.02.013_b0430","doi-asserted-by":"crossref","first-page":"e02395","DOI":"10.1128\/AAC.02395-16","article-title":"Characterization of \u03b2-D-N4-hydroxycytidine as a novel inhibitor of Chikungunya virus","volume":"61","author":"Ehteshami","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.013_b0435","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.3390\/v7122934","article-title":"Identification of a new ribonucleoside inhibitor of Ebola virus replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2022.02.013_b0440","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.48.10.3944-3953.2004","article-title":"A 7-deaza-adenosine analog is a potent and selective inhibitor of Hepatitis C Virus replication with excellent pharmacokinetic properties","volume":"48","author":"Olsen","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.013_b0445","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1021\/jm040068f","article-title":"Structure\u2013activity relationship of heterobase-modified 2\u2019-C-methyl ribonucleosides as inhibitors of Hepatitis C Virus RNA replication","volume":"47","author":"Eldrup","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.013_b0450","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/acsinfecdis.0c00829","article-title":"Antiviral activity of 7-substituted 7-deazapurine ribonucleosides, monophosphate prodrugs, and triphoshates against emerging RNA viruses","volume":"7","author":"Milisavljevic","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.013_b0455","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsinfecdis.7b00172","article-title":"Immucillins in infectious diseases","volume":"4","author":"Evans","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.013_b0460","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.05.013","article-title":"Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters","volume":"156","author":"Westover","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.013_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105180","article-title":"An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral","volume":"195","author":"Julander","year":"2021","journal-title":"Antiviral Res"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622000708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622000708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:00:14Z","timestamp":1761224414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622000708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1359644622000708"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.02.013","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleosides and emerging viruses: A new story","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}